Comparative efficacy in red blood cell exchange transfusions with different apheresis machines in patients with sickle cell disease
The purpose of this study is to compare the efficacy and side effects of two red blood cell exchange (RBCX) transfusion systems in sickle cell disease (SCD). The data is collected retrospectively from the January 2010 to March 2015. 447 RBCX transfusions were performed to 165 patients. Side effects, clinical and technical efficacy were compared in between procedures with Cobe Spectra (CS) and Spectra Optia (SO) systems. Furthermore a subgroup analyses was performed for 40 patients who had RBCX transfusions with both system at least two times. Vasoocclusive crises, preoperative period and foot ulcers (49.6, 13, and 15.2% respectively) were the common indications of RBCX transfusion. While the levels of post-RBCX HbS and the actual fraction of cells remaining (FCRa) were found significantly higher in the SO compared to CS system (p = 0.018 and p = 0.016 respectively), the rate of targeted hemoglobin S (HbS) levels (< 30%) were same in both. The length of procedure and replacement volume were significantly lower in SO compared to CS system (p = 0.025 and 0.044 respectively). Subgroup analyses of 40 patients did not reveal any statistically significant differences regarding post-procedure HbS levels, FCRa levels, replacement volume and procedure duration. The inter-rater correlation coefficient for FCRa was calculated to be 0.82. Serious adverse reactions were not observed from either system. Both systems are efficiently achieved the targeted post-procedure HbS level. The recently introduced SO apheresis system is as effective and safe as the CS system, which has been used for all indications of SCD for years.
KeywordsSickle cell disease Red blood cell exchange Cobe Spectra Spectra Optia
We thank to the apheresis unit staff for their cooperation.
This study was approved by the Institutional Medical and Health Sciences Experimental/Clinical Research Principles and Research Committee (Project No: KA15/148).
Compliance with Ethical Standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- 6.Hebbel RP (2009) Pathobiology of sickle cell disease. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop H, Furie B, McGlave P, Shattil SJ (eds) Hematology basic principles and practise, 5th edn. Elsevier, Amsterdam, pp 565–602Google Scholar
- 7.Wang WC (2009) Sickle cell anemia and other sickling syndromes. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, Means RT (eds) Wintrobe’s clinical hematology, Nineth edn. Lippincot Williams and Wilkins, Philadelphia, pp 1038–1082Google Scholar
- 9.Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML et al (2013) Guidelines on the use of therapeutic apheresis in clinical practice—evidence based approach from the writing committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 28:145–284CrossRefPubMedGoogle Scholar
- 11.Morris CR (2008) Mechanisms of vasculopathy in sickle cell disease and talasemia. Hematol Am Soc Hematol Educ Program 2008:177–185Google Scholar
- 12.Orimolade EA, Salawu L (2008) Immunohematological characteristics of Nigerian sickle cell disease patients with osteomyelitis. Turk J Hematol 25:145–148Google Scholar
- 15.Singer ST, Quirolo K, Nishi K, Hackney-Stephens E, Evans C, Vichinsky EP (1999) Erythrocytapheresis for chronically transfused children with sickle cell disease: an effective method for maintaining a low hemoglobin S level and reducing iron overload. J Clin Apher 14:122–125CrossRefPubMedGoogle Scholar
- 20.Poullin P, Sanderson F, Bernit E, Brun M, Berdah Y, Badens C (2016) Comparative evaluation of the depletion-red cell exchange program with the spectra optia and the isovolemic hemodilution-red cell exchange method with cobe spectra in sickle cell disease patients. J Clin Apher 31:429–433CrossRefPubMedGoogle Scholar